FDA Clears Luminex's MDx Respiratory Viral Panel | GenomeWeb
This article has been updated to include information from a conference call and Luminex's closing stock price.
 
NEW YORK (GenomeWeb News) – The US Food and Drug Administration has cleared Luminex’s molecular diagnostic panel for a dozen viruses that account for over 85 percent of respiratory viral infections, including various influenza strains, the company said today.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.